CRISPR THERAPEUTICS AG Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
CRISPR THERAPEUTICS AG (CRSP) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 246.29 thousand shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-25.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2019-02-25
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2018-12-31 was 10.04K shares.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2018-09-30 was 57.27K shares.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2018-06-30 was 65.97K shares.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2018-03-31 was 113.00K shares.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2018 was 246.29K shares, a 45.46% decline from fiscal 2017.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2017 was 451.55K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month |
|---|---|---|---|---|
| 2018-12-31 | 10.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | 67.31K shares derived: sum of 2 quarters · filed 2019-02-25 | 133.28K shares derived: sum of 3 quarters · filed 2019-02-25 | 246.29K shares 10-K · filed 2019-02-25 |
| 2018-09-30 | 57.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | 123.24K shares derived: sum of 2 quarters · filed 2018-11-07 | 236.24K shares 10-Q · filed 2018-11-07 | |
| 2018-06-30 | 65.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | 178.98K shares 10-Q · filed 2018-08-07 | ||
| 2018-03-31 | 113.00K shares 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | 451.55K shares 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |